Commercializing cell and gene therapies

April 5, 2017 Christoph Graener

New business models for clinical development and manufacturing require strategic partnerships among researchers, manufacturers and payers to fully realize the commercial opportunities.

Moderator: Morrie Ruffin – Adjuvant Partners

  • Boro Dropulic – Lentigen Technology Inc., A Miltenyi Biotec Company
  • Miguel Mulet – TiGenix NV
  • Peter Nell – Casebia Therapeutics

Previous Article
Stirring the entrepreneurial pot in Europe

Europe has many of the biggest pharma companies and best academic biomedical researchers. What is happening...

Next Article
Making early investment decisions: Incorporating flexibility into your R&D strategy

Strategic decisions made early in clinical development often have an impact on the downstream commercial po...